NPPA Releases Revised MRP for Anti-Cancer Medicines
Ministry of Chemicals and Fertilizers - Department of Pharmaceuticals · Health · Posted 28 OCT 2026 6:44PM
What happened
The National Pharmaceutical Pricing Authority released revised Maximum Retail Prices for 543 brands of anti-cancer medicines, effective November 9, 2026, following Trade Margin Rationalisation for 137 non-scheduled anti-cancer drugs.
Why it matters for UPSC
This initiative illustrates government intervention in healthcare pricing and regulation under social issues and governance, directly impacting the accessibility and affordability of critical medications like cancer treatments for citizens.
Key objectives
- NPPA released revised MRPs for 543 brands of anti-cancer medicines effective from November 9, 2026.
- Trade Margin Rationalisation (TMR) announced for 137 non-scheduled anti-cancer drugs to make treatment more affordable and address excessive trade margins.
- The revised price list includes immunotherapy medicines, Denosumab, Pegfilgrastim, and Bevacizumab used across multiple cancer treatments.